Status:

UNKNOWN

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

Lead Sponsor:

Emory University

Conditions:

Asthma

Eligibility:

All Genders

4-11 years

Phase:

PHASE4

Brief Summary

Asthma and gastroesophageal reflux disease (GERD) are common disorders, which although are not usually lethal, both have high morbidity, and high healthcare costs. Recent studies have demonstrated tha...

Detailed Description

GERD and asthma likely co-exist, and may be pathogenetically linked. However, it is controversial whether GERD per se is an important risk factor for severe asthma, and whether treatment of GERD and/o...

Eligibility Criteria

Inclusion

  • 4-11 years Informed Consent/ Assent Asthma Clinically normal laboratory results and physical exam

Exclusion

  • Unable or unwilling to give informed consent Unable to comply with study protocol Any preexisting condition that would require A PPI for a period of 6 months or more and/other major chronic illnesses.
  • Drug Allergies toPPI. At High risk for non-compliance and/or adherence.

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2010

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00237068

Start Date

March 1 2006

End Date

December 1 2010

Last Update

March 16 2011

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Emory Children's Center

Atlanta, Georgia, United States, 30322

2

Children's Center for Digestive Healthcare

Atlanta, Georgia, United States, 30342

3

Georgia Pediatric Pulmonology Associates/ CHOA

Atlanta, Georgia, United States, 30342

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. | DecenTrialz